Have investors forgotten about Micron (MU)? Amid all the attention surrounding coronavirus, it’s hard to argue if it feels that way. But with the chip giant expected to release earnings after market close tomorrow, the spotlight will be back on Micron.Ahead of the print, Susquehanna’s Mehdi Hosseini has been trimming estimates. Although, as the analyst notes, in the current climate it is hard to gauge earnings on a quarterly basis, the reduction is for earnings in FY20/21. The new targets are for EPS of $1.89/$4.39, down from the previous estimates of $2.26/$6.61.Nevertheless, Hosseini reiterates a Buy rating on Micron shares, along with a price target of $85. The potential upside from current levels is an impressive 96%. (To watch Hosseini’s track record, click here)The 4-star analyst said, “We expect MU's February-quarter results/May-quarter guide to meet our estimates (in-line with consensus) as supply chain disruption in China is expected to be offset...
This listing shows the latest news on trucking industry events or trade shows that have either been cancelled or postponed in the ongoing effort to contain the COVID-19 virus. ...
This listing shows the latest news on trucking industry events or trade shows that have either been cancelled or postponed in the ongoing effort to contain the COVID-19 virus. ...
When the economy transitions from expansion to contraction and the market transitions from a bull to a bear, investors can't expect all the same stocks and funds to outperform and the same investing strategies to continue to work.Economic fears due to the spread of the COVID-19 coronavirus has led the market to plummet in the past month, with the Dow Jones Industrial Average falling from the 30,000 level to under 19,000 earlier this week.Investors priorities flip from maximizing gains to minimizing risk, and buying volume rotates into brand new pockets of the market. The past few weeks of trading in the market may seem like total chaos, but a closer look reveals certain groups of stocks and funds are outperforming others.Here are eight ETFs to consider that could outperform during a U.S. recession.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for...
(Bloomberg) -- Record low prices for heavy Canadian crude have prompted one of the biggest operators in the oil sands to take the rare step of shutting production.Motivated by the “extremely low” prices, Suncor Energy Inc. announced on Tuesday that it will shut in one of its two so-called trains at its two-year-old, 194,000 barrel a day Fort Hills oil sands mine. The company also is delaying the start up of its MacKay River oil sands wells to May, after operations were halted in December because of a malfunction and fire.The move comes as the coronavirus pandemic slashes worldwide oil demand just as Saudi Arabia ramps up oil production in a price war with Russia, sending global oil benchmarks to the lowest prices in almost two decades. Western Canadian Select, the oil-sands benchmark, fell to $8.54 a barrel, which will be a record low if it settles at this price, data...
Nike reported fiscal third-quarter sales that topped expectations, even as the coronavirus outbreak generated a host of disruptions for the athletic-wear maker. Yahoo Finance Live breaks down the numbers....
One of the difficulties facing American investors during the COVID-19 outbreak is separating fact from fiction, rumor from truth and speculation from confirmation.President Donald Trump has said repeatedly that chloroquine and hydroxychloroquine can be used to treat the novel coronavirus, leading to panic buying and a shortage for patients who are prescribed the drugs for their approved uses.Here's a look at what investors need to know about these drugs. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.What Are Chloroquine, Hydroxychloroquine? Chloroquine and hydroxychloroquine are drugs approved by the FDA to treat malaria. Hydroxychloroquine is also approved to treat lupus and rheumatoid arthritis due to its anti-inflammatory properties. Hydroxychloroquine is a derivative of chloroquine that has a similar structure but different chemical and biological properties.Studies suggest chloroquine is less toxic to humans than hydroxychloroquine.Both drugs have been in...